Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XELOX versus FOLFOX as adjuvant therapy for operated colorectal cancer
ACTRN12610000509066Phase 3Completed
- Sponsor
- HeCOG
- Start
- Oct 2005
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of capecitabine, oxaliplatin, fluorouracil and folinic acid in colorectal cancer (CRC) and colon adenocarcinoma (2 arms), sponsored by HeCOG. Primary endpoint: 3-year disease-free survival. Started Oct 2005; status: completed.
02
Drugs
capecitabineoxaliplatinfluorouracilfolinic acid
03
Conditions
colorectal cancer (CRC)colon adenocarcinoma
Beyond the preview
Go deeper on ACTRN12610000509066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12610000509066.